Drug Profile
Satralizumab - Chugai Pharmaceuticals/Roche
Alternative Names: ENSPRYNG; RG-6168; SA-237; Satralizumab-mwgeLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Roche
- Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuromyelitis optica
- Phase III Encephalitis; Graves ophthalmopathy; Myasthenia gravis
- No development reported Rheumatoid arthritis
Most Recent Events
- 21 Mar 2024 Efficacy and adverse events data from the phase III LUMINESCE trial in Myasthenia gravis were released by Chugai Pharmaceutical
- 15 Feb 2024 Roche announces intention to submit regulatory application for Graves ophthalmopathy in 2025 (Roche pipeline, February 2024)
- 15 Nov 2023 Phase-III clinical trials in Graves ophthalmopathy in China (SC) (NCT06106828)